Search

everythinglearnresearchcommunity

for

Search:↓

PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.

A user is seeking recommendations for doctors who perform Dutasteride mesotherapy in NJ or PA, as they are having trouble finding one through Google. The conversation focuses on finding a suitable provider for this specific hair loss treatment.

The conversation discusses using 2-deoxy-d-ribose (2DDR) for hair regrowth, with users sharing mixed experiences and side effects like hair loss in new areas and increased anxiety. The original poster plans to continue testing and comparing it to minoxidil, noting potential instability in 2DDR formulations.

A 26-year-old is experiencing hair thinning and has received conflicting diagnoses of androgenetic alopecia and telogen effluvium. They are considering treatments like dutasteride, oral and topical minoxidil, and are unsure whether to start treatment or pursue further diagnosis like a scalp biopsy.

User discusses potential hair loss treatment SCUBE3 and shares mixed opinions on its effectiveness. One user reports positive results after applying SCUBE3 following microneedling.

Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.

Spironolactone, finasteride, and dutasteride are discussed for hair maintenance, with concerns about testosterone and side effects like gynecomastia. Spironolactone is noted for use in both bodybuilding and hormone therapy, with low doses considered for minimizing side effects.

Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.

A 24-year-old with early hair loss is managing it with finasteride, minoxidil, and dutasteride, and is considering using a hair system for more styling options while maintaining transparency. They emphasize confidence and self-expression over hair, viewing it as an amplifier rather than a foundation.

Spironolactone may help reverse hair miniaturization in AGA. Combining it with minoxidil can promote thicker hair.

The conversation discusses using high molecular weight hyaluronic acid after microneedling to form a protective barrier, though it's considered expensive and offers marginal improvement. Users share experiences with different microneedling tools like derma rollers, dermastamps, and Dr. Pen, with some opting not to use any products on the scalp.

The conversation is about personal experiences with Anagenic Pyrilutamid for hair loss and what carriers people use with it. No specific treatments or outcomes are mentioned.

The user shares their experience with a hair system, noting no one noticed the change except their girlfriend. They discuss the learning curve, maintenance tips, and their satisfaction with the results, feeling more confident and optimistic.

Users discussed experiences with Everychem's solution similar to PP405 for hair loss, noting some positive results like increased hair thickness and new growth. There was skepticism about the product's legitimacy and safety, with some users reporting early signs of effectiveness and others expressing concerns about the lack of evidence and safety profiles.

Corticosterone inhibits GAS6, affecting hair follicle stem-cell activity, with potential implications for stress-related hair loss. Ashwagandha and Vitamin K are suggested for reducing cortisol, but their effectiveness is debated.

Hopeful treatments for hair loss, including Verteporfin, Androgen Receptor Degradation, and SCUBE3. These treatments offer potential solutions to slow or stop the effects of androgens on the scalp.

Some individuals experience side effects from 5AR inhibitors like finasteride and are considering hair transplants without these medications, with some opting for surgeons like Dr. Zarev. Others are exploring alternative treatments and waiting for new medications in development, while some discuss managing side effects through lifestyle changes or additional medications.

Clascoterone 5% solution is discussed as a potential new treatment for hair loss, offering an alternative for those who can't use finasteride or need additional options beyond minoxidil. Concerns about cost, effectiveness, and safety compared to existing treatments like RU58841 and finasteride are highlighted.

A user with androgenic alopecia seeks advice on making topical spironolactone from pills due to poor reactions to the oral form and its unavailability in their country. They are looking for guidance on preparing it themselves.

GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.

Clascoterone, an acne treatment that blocks DHT, is being developed for scalp use against hair loss. The conversation also mentions Minoxidil, finasteride, and RU58841 as treatments.

The conversation discusses an extensive hair loss treatment regimen including dutasteride, GT20029, RU58841, pyrilutamide, minoxidil, microneedling, ketoconazole shampoo, and experimental compounds. The user humorously describes their approach as a comprehensive strategy to combat hair loss while maintaining hair growth.

Oral minoxidil treatment increased hair density and shaft caliber in AGA patients. Side effects included hypertrichosis and lower extremity edema, with younger patients experiencing fewer side effects.

Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.

Pyrilutimide and CB-03-01, two treatments for hair loss, have similar clinical trial results despite different binding affinities to androgen receptors. Factors other than binding affinity, like the time a drug stays bound to the receptor, may influence their effectiveness.

This user has conducted data scraping of 365 Reddit posts on the hairloss drug Pyrilutamide over the last year to analyse efficacy and side effects. The findings, which are available in a 19 page report with graphs, suggest that 22% of Pyrilutamide users experience positive results while 63% experience symptoms. A larger analytics project is proposed for other drugs with enough demand.

The conversation discusses using estradiol mesotherapy to replicate hormone replacement therapy results while minimizing systemic exposure. It also covers the use of Spironolactone cream, which reportedly has no systemic side effects, and the potential risks of using bicalutamide and Spironolactone in men.

GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.

The conversation discusses GT20029 as a potential hair loss treatment that could act like a cure by targeting androgen receptors in scalp hair follicles. Specific treatments mentioned include GT20029, with a user expressing hope that it could make male pattern baldness obsolete.

A woman who has been experiencing hair loss for several years, and her question of whether there is any benefit to getting a biopsy to check if it's AGA or diffuse alopecia areata when no cure or very effective treatment exists. Treatments such as spironolactone and Minoxidil/finasteride/RU58841 have previously been discussed.